Loading
FRK is a SRC-related kinase that mostly acts as a brake on growth; it is a minor off-target of approved kinase inhibitors and is lost or mutated in some liver and brain cancers. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A nuclear and cytoplasmic SRC-family kinase expressed in epithelial tissues, brain and liver; it phosphorylates PTEN and retinoblastoma protein, slowing the cell cycle.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | all% | Signalling protein present in most cells (FRK kinase); drugs act on the pathway rather than on a mutation that selects patients, so no prevalence applies. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"FRK kinase" OR ABSTRACT:"FRK kinase" OR TITLE:"FRK" OR ABSTRACT:"FRK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FRK kinase, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/frk.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/frk.json. Licence CC BY-NC 4.0.